Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Nevada-based PDL BioPharma, Inc. said it will no longer pursue a proposed acquisition of Neos Therapeutics.
Novartis may soon be looking to sell off its generics subsidiary Sandoz.
Roche will plunk down $1.9M to acquire Flatiron Health, which has previously been backed by GV, as well as Roche.
Investors and analysts had been encouraging Gilead to acquire something for a long time, so they were mostly happy when it bought Kite Pharma in September.
Hayao will also form a JV with GNC to make and distribute GNC supplements in China.
The Branford, CT-based company was founded in 2017 and plans to list on the Nasdaq under the symbol BTAI.
The acquisition will strengthen Charles River’s position as a global early-stage CRO, expanding its client base and service portfolio.
It’s the end of the road for Cambridge, MA based Enumeral Biomedical.
According to sources reported by Reuters, potential buyers have been winnowed down to two pharma companies, three private equity funds, and a consortium of buyers.
Companies including Sanofi, J&J, Nestle have dropped out.